Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Aadi Bioscience Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Dave Lennon

İcra Kurulu Başkanı

US$2.1m

Toplam tazminat

CEO maaş yüzdesi	7.5%
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2.3yrs
Yönetim Kurulu ortalama görev süresi	3.2yrs

Son yönetim güncellemeleri

Recent updates

Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop

Jul 03

Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?

Jul 02

Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)

May 10

Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Mar 07

Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Feb 12

Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Dec 16

Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Nov 10

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Oct 03

Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Jun 28

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Mar 04

Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors

Oct 12

What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today

Nov 27

Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning

Nov 25

CEO Tazminat Analizi

Dave Lennon'un ücretlendirmesi Aadi Bioscience'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$65m
Mar 31 2024	n/a	n/a	-US$69m
Dec 31 2023	US$2m	US$160k	-US$66m

Tazminat ve Piyasa: Dave 'nin toplam tazminatı ($USD 2.14M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 677.23K ).

Tazminat ve Kazançlar: Dave şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Dave Lennon (53 yo)

less than a year

Görev süresi

US$2,135,687

Tazminat

Mr. David J. Lennon, Ph.D. also known as Dave, is the Treasurer at Alliance for Regenerative Medicine from April, 2022. He is the CEO of Satellite Bio. He serves as President and CEO & Director at Aadi Bio...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Lennon	President	less than a year	US$2.14m	Veri yok
Scott Giacobello	CFO, Treasurer	2.9yrs	US$1.97m	0% $ 0
Stephen Rodin	Senior VP of Legal & General Counsel	2.7yrs	Veri yok	Veri yok
Raymond Steitz	Senior VP of Human Resources & Chief Human Resources Officer	2.3yrs	Veri yok	Veri yok
Bryan Ball	Chief Technical Operations Officer	2.2yrs	Veri yok	0.41% $ 196.0k

2.3yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: AADI 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Lennon	President	less than a year	US$2.14m	Veri yok
Caley Castelein	Independent Chairman of the Board	3.2yrs	US$258.91k	0.080% $ 38.6k
Emma Reeve	Independent Director	3.1yrs	US$240.91k	0% $ 0
Anupam Dalal	Independent Director	3.2yrs	US$235.91k	0.0046% $ 2.2k
Karin Hehenberger	Independent Director	3.2yrs	US$227.41k	0% $ 0
Richard Maroun	Independent Director	7.7yrs	US$240.91k	0% $ 0
Mohammad Hirmand	Independent Director	1.6yrs	US$345.60k	0% $ 0
Behzad Aghazadeh	Independent Director	3.2yrs	US$225.41k	0% $ 0

3.2yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AADI 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.2 yıldır).

Aadi Bioscience Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Founder & Executive Chairman notifies of intention to sell stock

Aadi Bioscience, Inc., Annual General Meeting, Jun 11, 2024

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

Aadi Bioscience, Inc. Announces Chief Executive Officer Changes

Founder notifies of intention to sell stock

Recent updates

Aadi Bioscience, Inc. Approves Plan of Termination That Will Result in Workforce Reduction of 22 Employees, Representing Approximately 32% of the Workforce

Aadi Bioscience Provides PRECISION1 Trial Updates

Consensus estimates of losses per share improve by 12%

Price target decreased by 14% to US$10.00

New major risk - Financial position

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Aadi Bioscience, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Small Cap Comp Value Index

Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop

Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?

Founder & Executive Chairman notifies of intention to sell stock

Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting

Consensus revenue estimates decrease by 14%, EPS upgraded

Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)

New minor risk - Profitability

Forecast to breakeven in 2026

First quarter 2024 earnings released: US$0.68 loss per share (vs US$0.57 loss in 1Q 2023)

Aadi Bioscience, Inc., Annual General Meeting, Jun 11, 2024

Full year 2023 earnings released: US$2.44 loss per share (vs US$2.69 loss in FY 2022)

Aadi Bioscience, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Founder notifies of intention to sell stock

Aadi Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Price target decreased by 67% to US$11.67

Aadi Bioscience, Inc. Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations

Founder notifies of intention to sell stock

Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Market cap size

New minor risk - Share price stability

Aadi Bioscience, Inc. Announces Chief Executive Officer Changes

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Founder notifies of intention to sell stock

Consensus EPS estimates fall by 10%

Second quarter 2023 earnings: EPS misses analyst expectations

Aadi Bioscience, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Founder notifies of intention to sell stock

Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Consensus revenue estimates increase by 11%, EPS downgraded

Price target decreased by 8.8% to US$38.75

First quarter 2023 earnings released: US$0.57 loss per share (vs US$0.66 loss in 1Q 2022)

Founder notifies of intention to sell stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience, Inc. Announces Management Changes

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Aadi Bioscience, Inc. Announces Executive Changes, Effective January 1, 2023

Aadi Bioscience, Inc. Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-Sirolimus at 34th EORTC-NCI-AACR Symposium

Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors

A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)

Aadi Bioscience: Taking mTOR Inhibition To The Next Level

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aadi Bioscience, Inc. Reports Impairment of Intangible Asset for the Second Quarter Ended June 30, 2022

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Microcap Value Index

Aadi Bioscience to enter Russell 2000 and Russell 3000 indexes

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

Aadi Bioscience, Inc. Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Present at 2022 ASCO Annual Meeting

Consensus revenue estimates increase by 112%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders

Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services

High number of new directors

Aadi Bioscience, Inc. Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes

Full year 2021 earnings: EPS and revenues exceed analyst expectations